35
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Prognostic Value and Outcome for ETV6/RUNX1-Positive Pediatric Acute Lymphoblastic Leukemia: A Report From the South China Children’s Leukemia Group

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          To analyzed the outcome of ETV6/RUNX1-positive pediatric acute B lymphoblastic leukemia (B-ALL) with the aim of identifying prognostic value.

          Method

          A total of 2,530 pediatric patients who were diagnosed with B-ALL were classified into two groups based on the ETV6/RUNX1 status by using a retrospective cohort study method from February 28, 2008, to June 30, 2020, at 22 participating ALL centers.

          Results

          In total, 461 (18.2%) cases were ETV6/RUNX1-positive. The proportion of patients with risk factors (age <1 year or ≥10 years, WB≥50×10 9/L) in ETV6/RUNX1-positive group was significantly lower than that in negative group ( P<0.001), while the proportion of patients with good early response (good response to prednisone, D15 MRD < 0.1%, and D33 MRD < 0.01%) in ETV6/RUNX1-positive group was higher than that in the negative group ( P<0.001, 0.788 and 0.004, respectively). Multivariate analysis of 2,530 patients found that age <1 or ≥10 years, SCCLG-ALL-2016 protocol, and MLL were independent predictor of outcome but not ETV6/RUNX1. The EFS and OS of the ETV6/RUNX1-positive group were significantly higher than those of the negative group (3-year EFS: 90.11 ± 4.21% vs 82 ± 2.36%, P<0.0001, 3-year OS: 91.99 ± 3.92% vs 88.79 ± 1.87%, P=0.017). Subgroup analysis showed that chemotherapy protocol, age, prednisone response, and D15 MRD were important factors affecting the prognosis of ETV6/RUNX1-positive children.

          Conclusions

          ETV6/RUNX1-positive pediatric ALL showed an excellent outcome but lack of independent prognostic significance in South China. However, for older patients who have the ETV6/RUNX1 fusion and slow response to therapy, to opt for more intensive treatment.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          Acute lymphoblastic leukaemia.

          Acute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous exposures, genetic susceptibility, and chance have roles. Survival in paediatric acute lymphoblastic leukaemia has improved to roughly 90% in trials with risk stratification by biological features of leukaemic cells and response to treatment, treatment modification based on patients' pharmacodynamics and pharmacogenomics, and improved supportive care. However, innovative approaches are needed to further improve survival while reducing adverse effects. Prognosis remains poor in infants and adults. Genome-wide profiling of germline and leukaemic cell DNA has identified novel submicroscopic structural genetic changes and sequence mutations that contribute to leukaemogenesis, define new disease subtypes, affect responsiveness to treatment, and might provide novel prognostic markers and therapeutic targets for personalised medicine. Copyright © 2013 Elsevier Ltd. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The MLL recombinome of acute leukemias in 2013

            Chromosomal rearrangements of the human MLL (mixed lineage leukemia) gene are associated with high-risk infant, pediatric, adult and therapy-induced acute leukemias. We used long-distance inverse-polymerase chain reaction to characterize the chromosomal rearrangement of individual acute leukemia patients. We present data of the molecular characterization of 1590 MLL-rearranged biopsy samples obtained from acute leukemia patients. The precise localization of genomic breakpoints within the MLL gene and the involved translocation partner genes (TPGs) were determined and novel TPGs identified. All patients were classified according to their gender (852 females and 745 males), age at diagnosis (558 infant, 416 pediatric and 616 adult leukemia patients) and other clinical criteria. Combined data of our study and recently published data revealed a total of 121 different MLL rearrangements, of which 79 TPGs are now characterized at the molecular level. However, only seven rearrangements seem to be predominantly associated with illegitimate recombinations of the MLL gene (∼90%): AFF1/AF4, MLLT3/AF9, MLLT1/ENL, MLLT10/AF10, ELL, partial tandem duplications (MLL PTDs) and MLLT4/AF6, respectively. The MLL breakpoint distributions for all clinical relevant subtypes (gender, disease type, age at diagnosis, reciprocal, complex and therapy-induced translocations) are presented. Finally, we present the extending network of reciprocal MLL fusions deriving from complex rearrangements.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group Study AALL0232

              Survival for children and young adults with high-risk B-acute lymphoblastic leukemia has improved significantly, but 20% to 25% of patients are not cured. Children's Oncology Group study AALL0232 tested two interventions to improve survival.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Oncol
                Front Oncol
                Front. Oncol.
                Frontiers in Oncology
                Frontiers Media S.A.
                2234-943X
                20 December 2021
                2021
                : 11
                : 797194
                Affiliations
                [1] 1 Children’s Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou, China
                [2] 2 Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University , Guangzhou, China
                [3] 3 Department of Paediatrics, Sun Yat-sen University First Affiliated Hospital , Guangzhou, China
                [4] 4 Department of Hematology and Oncology, Shenzhen Children’s Hospital , Shenzhen, China
                [5] 5 Department of Paediatrics, Guangxi Medical University First Affiliated Hospital , Nanning, China
                [6] 6 Department of Paediatrics, Southern Medical University Zhujiang Hospital , Guangzhou, China
                [7] 7 Department of Hematology, Hunan Children’s Hospital , Changsha, China
                [8] 8 Department of Paediatrics, Second Xiangya Hospital of Central South University , Changsha, China
                [9] 9 Department of Paediatrics, Southern Medical University Nanfang Hospital , Guangzhou, China
                [10] 10 Department of Paediatrics, Huizhou Central People’s Hospital , Huizhou, China
                [11] 11 Department of Paediatrics, First Affiliated Hospital of Nanchang University , Nanchang, China
                [12] 12 Department of Paediatrics, Third Affiliated Hospital of Sun Yat-sen University , Guangzhou, China
                [13] 13 Department of Paediatrics, Sun Yat-sen University Cancer Center , Guangzhou, China
                [14] 14 Department of Hematology, Guangzhou Women and Children’s Medical Center , Guangzhou, China
                [15] 15 Department of Paediatrics, Liuzhou People’s Hospital , Liuzhou, China
                [16] 16 Department of Paediatrics, Huizhou First People’s Hospital , HuiZhou, China
                [17] 17 Department of Paediatrics, Affiliated Hospital of Guangdong Medical University , Zhanjiang, China
                [18] 18 Department of Paediatrics, The First Affiliated Hospital of Shantou University Medical College , Shantou, China
                [19] 19 Department of Paediatrics, Hunan Provincial People’s Hospital , Changsha, China
                [20] 20 Department of Paediatrics, Zhongshan People’s Hospital , Zhongshan, China
                [21] 21 Department of Paediatrics, Guangzhou First People’s Hospital , Guangzhou, China
                [22] 22 Department of Paediatrics, Boai Hospital of Zhongshan , Zhongshan, China
                [23] 23 Department of Paediatrics, Hong Kong Children Hospital and Prince of Wales Hospital, The Chinese University of Hong Kong , Hong Kong, Hong Kong SAR, China
                Author notes

                Edited by: Anna Maria Testi, Sapienza University of Rome, Italy

                Reviewed by: Paola De Lorenzo, University of Milano Bicocca, Italy; Yasser Wali, Sultan Qaboos University, Oman

                *Correspondence: Jian-pei Fang, fangjpei@ 123456mail.sysu.edu.cn

                †These authors have contributed equally to this work and share first authorship

                This article was submitted to Hematologic Malignancies, a section of the journal Frontiers in Oncology

                Article
                10.3389/fonc.2021.797194
                8722219
                34988026
                fa503c5c-9c0a-4f6e-b340-ffcb782ed905
                Copyright © 2021 Qiu, Xu, Luo, Mai, Liao, Yang, Zheng, Wan, Wu, Liu, Chen, Chen, Sun, Jiang, Long, Chen, Li, Li, Huang, Ling, Lin, Wen, Kuang, Feng, Ye, Wu, He, Li, Wang, Kong, Xu, Li and Fang

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 19 October 2021
                : 29 November 2021
                Page count
                Figures: 4, Tables: 5, Equations: 0, References: 40, Pages: 15, Words: 7805
                Categories
                Oncology
                Original Research

                Oncology & Radiotherapy
                etv6/runx1,acute b lymphoblastic leukemia,outcome,prognosis,multicenter cohort study

                Comments

                Comment on this article